Protected intake, payment, prescribing, and care enrollment reopen in September.

PCOS Treatments: What the Evidence Shows

Jul 7, 2026 · 4 min readRolf Hoefer, Ph.D.

5 sources reviewedMedically reviewed by Amy Bingaman, MD, MSCP, FACOGArticle updated Jul 14, 2026Our editorial process

The short answer

The best polycystic ovary syndrome (PCOS) treatment depends on the problem being treated. Metformin may be used for metabolic concerns, letrozole or clomiphene for ovulation, anti-androgens for selected androgen symptoms, and weight-management medicines for eligible patients. Comparing them in one ranked list is misleading because they serve different goals. This is a selected evidence review, not a systematic or comprehensive review of every polycystic ovary syndrome study. [1]

What you’ll learn

  • Polycystic ovary syndrome (PCOS) does not have one treatment ranking because medicines used for metabolic health, fertility, excess hair, and weight address different goals.
  • Metformin, letrozole, liraglutide, anti-androgens, and clomiphene cannot be fairly ordered by simply counting study findings.
  • Metabolic and cardiovascular screening can remain important after menopause even when fertility treatment is no longer relevant.

Bottom line

Polycystic ovary syndrome (PCOS) treatment starts with the problem that needs treatment. A medicine used to induce ovulation should not be ranked against one used for glucose control, weight management, or excess hair as if they were competing for the same job.

The earlier version of this page did exactly that. It ranked treatments by the number of findings extracted into our evidence database. That count was not comprehensive, and it mixed studies with fundamentally different goals. We have removed the ranking.

This page reviews selected evidence. It is not a systematic or comprehensive review of every polycystic ovary syndrome treatment study.

Treatment depends on the goal

Treatment depends on the goal
Main goalOptions that may be discussedImportant context
Glucose and metabolic healthMetformin, nutrition, physical activity, and other metabolic treatment when indicatedBlood glucose, cholesterol, blood pressure, kidney function, and overall cardiovascular risk matter.
Fertility and ovulationLetrozole or clomiphene in appropriate premenopausal patientsThese treatments are not an all-purpose polycystic ovary syndrome therapy and are generally not relevant after menopause.
Weight managementLifestyle support and approved weight-management medicines for eligible patientsEligibility, side effects, muscle preservation, and long-term access matter.
Excess hair or acneSelected hormonal or anti-androgen approaches, plus dermatologic treatmentPregnancy potential, blood pressure, potassium, and other medicines can change the plan.
Irregular or heavy bleeding before menopauseEndometrial protection and cycle management based on individual riskNew bleeding after menopause requires evaluation rather than routine polycystic ovary syndrome treatment.

What the selected studies found

One study reported improvements in menstrual regularity, body mass index, metabolic markers, and hormonal measures after six months of metformin. [1] A letrozole and clomiphene comparison measured follicle development in people pursuing ovulation. [2] A liraglutide and metformin comparison focused on glucose response in women with obesity and polycystic ovary syndrome. [3]

Other cited studies addressed hirsutism with cyproterone acetate or spironolactone [4], or live birth with clomiphene or metformin [5]. These are different outcomes in different populations. The results can inform specific decisions, but they cannot support one overall treatment order.

What changes after menopause

Ovulation-induction treatment is no longer the focus after natural menopause, but a history of polycystic ovary syndrome can still be relevant. Diabetes, cholesterol, blood pressure, sleep apnea, and cardiovascular risk deserve attention based on current health and established screening guidance.

New facial hair, rapidly worsening acne, scalp hair loss, deepening voice, or other virilizing changes after menopause should not automatically be attributed to an old polycystic ovary syndrome diagnosis. A clinician may need to look for a new source of androgen excess.

Postmenopausal bleeding also needs prompt evaluation. It should not be managed as ordinary cycle irregularity.

Safety and practical limits

Each treatment has its own precautions. Metformin use depends partly on kidney function and gastrointestinal tolerance. Anti-androgen treatment can affect blood pressure, potassium, pregnancy risk, and medicine interactions. Weight-management medicines have separate eligibility rules and adverse effects. Fertility medicines require specialist context and do not belong in a postmenopausal treatment plan.

Important red flags include postmenopausal bleeding, rapid new facial-hair growth, a deepening voice, or other sudden virilizing changes. These symptoms need evaluation rather than being assumed to be part of a longstanding polycystic ovary syndrome history.

The evidence is limited by the different goals, populations, and outcomes represented in polycystic ovary syndrome trials. A result about ovulation cannot answer a question about cardiovascular risk or symptom treatment after menopause.

What this review includes

We retained selected cited comparisons but removed the unsupported ranking. We did not search every database, screen all eligible polycystic ovary syndrome trials, or formally grade every outcome. The page therefore explains what the reviewed studies can tell us without pretending they measure the total evidence behind each treatment.

What to ask your clinician

  • Which polycystic ovary syndrome related risk or symptom are we treating now?
  • What metabolic and cardiovascular screening do I need at my age?
  • Could new acne, hair changes, or bleeding point to something other than polycystic ovary syndrome?
  • What benefits and side effects should we track for the chosen treatment?
  • When should the plan be reassessed?

References

[1] Akram W, Nori W, Zghair MAG. Metformin effect on internal carotid artery blood flow assessed by area under the curve of carotid artery Doppler in women with polycystic ovarian syndrome. World Journal of Clinical Cases. 2023;11(6):1318-1329. doi:10.12998/wjcc.v11.i6.1318 https://doi.org/10.12998/wjcc.v11.i6.1318

[2] Bayar Ü, Basaran M, Kiran S, Coskun A, Gezer S. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertility and Sterility. 2006;86(5):1447-1451. doi:10.1016/j.fertnstert.2006.04.026 https://doi.org/10.1016/j.fertnstert.2006.04.026

[3] Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. Journal of Ovarian Research. 2015;8(1). doi:10.1186/s13048-015-0161-3 https://doi.org/10.1186/s13048-015-0161-3

[4] Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long‐term therapy of hirsute patients. Clinical Endocrinology. 2000;52(5):587-594. doi:10.1046/j.1365-2265.2000.00982.x https://doi.org/10.1046/j.1365-2265.2000.00982.x

[5] Pereira K, Kreider KE. Caring for women with polycystic ovary syndrome. The Nurse Practitioner. 2017;42(2):39-47. doi:10.1097/01.npr.0000480586.24537.64 https://doi.org/10.1097/01.npr.0000480586.24537.64

Common questions

What is the best treatment for PCOS?

There is no single best treatment. The plan depends on whether the priority is metabolic health, fertility, irregular bleeding, acne, excess hair, or weight management.[1][2][3][4][5]

Does metformin treat PCOS?

Metformin can improve glucose-related and metabolic measures in selected people with polycystic ovary syndrome (PCOS). Whether it is useful depends on the person's metabolic risks and treatment goals.[1]

Are letrozole and clomiphene relevant after menopause?

These medicines are used for ovulation induction, so they are generally not relevant after natural menopause. Their presence in the earlier all-purpose ranking showed why unlike treatment goals should not have been combined.[2][5]

Why was the earlier ranking removed?

It counted extracted findings from a limited evidence set and mixed treatments intended for very different outcomes. It did not measure the complete polycystic ovary syndrome (PCOS) evidence base.[1][2][3][4][5]

Related in Weight loss & metabolic health

Insulin resistance & prediabetesPCOS and Ultrasound After Menopause: What It Can ShowUltrasound can show ovarian size, follicle pattern, cysts, masses, uterine findings, or endometrial thickness, but it cannot by itself diagnose or rule out the current significance of polycystic ovary syndrome after menopause. The 2023 international guideline says ultrasound is not required for adult diagnosis when irregular cycles and hyperandrogenism are present, and the Endocrine Society notes diagnosis is problematic in menopausal women. After menopause, the useful question is why imaging is being ordered: pelvic pain, bleeding, a mass concern, hormone-therapy bleeding, or separate metabolic and androgen-risk review. [1] [2] [3]Jul 7, 2026 · 7 min readInsulin resistance & prediabetesPCOS and Hair Thinning After Menopause: What to CheckPolycystic ovary syndrome history can matter when scalp hair thins after menopause, but it should not be the whole explanation. The 2023 international guideline says female-pattern hair loss and acne alone are relatively weak predictors of biochemical hyperandrogenism, while new-onset, severe, or worsening hyperandrogenism needs further investigation. The safer first step is to separate gradual part widening from sudden shedding, scalp disease, medication or weight-loss triggers, thyroid or iron clues, and rapid androgen changes such as new hirsutism, severe acne, voice change, or virilization. [1]Jul 7, 2026 · 9 min readInsulin resistance & prediabetesHow to Lower A1C After Menopause: What Can Change FastA1C (hemoglobin A1c), the three-month blood sugar marker, can improve after menopause, but it should be judged over weeks to months because it reflects average blood glucose over the past 3 months. NIDDK lists prediabetes as 5.7% to 6.4% and diabetes as 6.5% or above. Faster daily glucose changes can happen with food pattern, activity, sleep, medication review, and prescription treatment when indicated. In the Diabetes Prevention Program, 3,234 high-risk adults had 58% lower diabetes incidence with structured lifestyle and 31% lower incidence with metformin versus placebo over 2.8 years. [1] [2] [3]Jul 7, 2026 · 9 min readInsulin resistance & prediabetesInositol Side Effects: PCOS, Menopause, and Safety ChecksInositol side effects are usually mild in the polycystic ovary syndrome evidence, and myo-inositol likely causes fewer gastrointestinal adverse events than metformin. The important caveat is that most trials in the 2024 guideline review did not report adverse events, long-term safety data are limited, and supplement quality and dose can vary. After 40 or after menopause, inositol should be a monitored supplement discussion, not a substitute for glucose, blood pressure, lipid, waist, sleep, androgen, or bleeding evaluation. [1] [2]Jul 7, 2026 · 8 min read